

## **Investor Relations policy**

Veloxis intends and endeavours to maintain an open and continuous dialogue with existing and potential shareholders, stakeholders, and the general public. The Company aims for a high degree of openness and to effectively communicate information, respecting the principle of equal treatment of all market players.

Our ambition is to ensure fair pricing of the Company's shares in order to reflect the Company's willingness to generate higher earnings for its shareholders.

In compliance with the disclosure requirements of the NASDAQ OMX Copenhagen, Veloxis Pharmaceuticals A/S will publish quarterly reports on the Company's development, including relevant financial information. In addition, Veloxis Pharmaceuticals A/S will publish details about the Company where such information is considered important to the pricing of its shares. The Company maintains an insider register and will publish any changes to certain insiders' shareholdings in accordance with the rules that apply for NASDAQ OMX Copenhagen. Such publication will be made immediately after the transaction.

Veloxis Pharmaceuticals A/S has adopted in-house rules, which stipulate that insiders may only purchase and sell shares in Veloxis Pharmaceuticals A/S during a period of 6 weeks after the Company's publication of interim financial statements. Such information will first be published and will immediately thereafter be available here at the Company Web site and be submitted to shareholders and others who via the Company Web site have requested the receipt of e-mail news from the Company.